review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Siok-Bian Ng | Q60374588 |
P2093 | author name string | Wee-Joo Chng | |
Anand D Jeyasekharan | |||
Tae-Hoon Chung | |||
Sanjay de Mel | |||
Yingting Mok | |||
Gwyneth Shook-Ting Soon | |||
P2860 | cites work | BCoR, a novel corepressor involved in BCL-6 repression | Q22254616 |
MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
Widespread microRNA repression by Myc contributes to tumorigenesis | Q24647067 | ||
Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway | Q24657973 | ||
Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells | Q26740953 | ||
Therapeutic options in peripheral T cell lymphoma | Q26748857 | ||
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma | Q27026544 | ||
OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors | Q27728475 | ||
AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol | Q27824792 | ||
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
Human CD38: a glycoprotein in search of a function | Q28252788 | ||
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma | Q28266655 | ||
MLL targets SET domain methyltransferase activity to Hox gene promoters | Q28609771 | ||
Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma | Q44552844 | ||
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity | Q45217684 | ||
p53, K-ras, c-kit and beta-catenin gene mutations in sinonasal NK/T-cell lymphoma in Korea and Japan. | Q45219269 | ||
Epstein-Barr virus-mediated dysregulation of human microRNA expression | Q45388785 | ||
Low frequency of HLA-A*0201 allele in patients with Epstein-Barr virus-positive nasal lymphomas with polymorphic reticulosis morphology | Q45741924 | ||
Nasal lymphomas in Japan: a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene | Q45745453 | ||
Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. | Q45754031 | ||
Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma | Q47240802 | ||
EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes. | Q47447684 | ||
A major turning point in NK/T-cell lymphoma? | Q48222546 | ||
Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation | Q49414498 | ||
Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. | Q50055394 | ||
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro | Q42815166 | ||
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells | Q42827073 | ||
Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan | Q44535044 | ||
Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. | Q51101587 | ||
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. | Q51403316 | ||
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. | Q51732144 | ||
Hypermethylation of PRDM1/Blimp-1 promoter in extranodal NK/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation. | Q52845594 | ||
Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. | Q53597468 | ||
Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. | Q53664277 | ||
Frequent mutations of Fas gene in nasal NK/T cell lymphoma. | Q53966209 | ||
Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma. | Q54342283 | ||
The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers | Q56593831 | ||
Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China | Q57214947 | ||
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma | Q58742961 | ||
Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q61053530 | ||
Mutations of the p53 gene in nasal NK/T-cell lymphoma | Q73711198 | ||
Comparative genomic hybridization study of nasal-type NK/T-cell lymphoma | Q73774958 | ||
TET2 and DNMT3A mutations in human T-cell lymphoma | Q83175924 | ||
Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling | Q83367663 | ||
Lack of evidence that HACE1 is not a tumor suppressor gene in NKTCL: to the editor-in-chief. Authors' reply | Q86967267 | ||
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions | Q29614512 | ||
Role of platelet-derived growth factors in physiology and medicine | Q29615222 | ||
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations | Q29615392 | ||
p53 in health and disease | Q29619939 | ||
Epigenetic inactivation of the miR-124-1 in haematological malignancies | Q31008825 | ||
P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan | Q31038356 | ||
MicroRNA profiling of Epstein-Barr virus-associated NK/T-cell lymphomas by deep sequencing | Q31080906 | ||
Gene mutation analysis of sinonasal lymphomas in Indonesia | Q33238945 | ||
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters | Q33402136 | ||
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). | Q33408536 | ||
Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling | Q33566663 | ||
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma | Q33585243 | ||
Checkpoint inhibitors in hematological malignancies | Q33651495 | ||
Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type | Q33677463 | ||
High-resolution genome-wide analysis identified recurrent genetic alterations in NK/T-cell lymphoma, nasal type, which are associated with disease progression | Q33839279 | ||
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion | Q33978930 | ||
The HLA system. First of two parts | Q34023681 | ||
Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas | Q34079271 | ||
Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma | Q34216713 | ||
Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells | Q34544793 | ||
Prognostic implication of morphology, cyclinE2 and proliferation in EBV-associated T/NK lymphoproliferative disease in non-immunocompromised hosts | Q34677558 | ||
TAK1-ECSIT-TRAF6 complex plays a key role in the TLR4 signal to activate NF-κB | Q34737822 | ||
Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets | Q34898306 | ||
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression | Q34995467 | ||
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | Q35068768 | ||
p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease | Q35747125 | ||
Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations | Q35788068 | ||
Consistent patterns of allelic loss in natural killer cell lymphoma | Q35829661 | ||
Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma | Q35859357 | ||
Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring | Q36048767 | ||
Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type | Q36232164 | ||
RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC. | Q36259257 | ||
HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms | Q36495194 | ||
Expression of microRNA-10a, microRNA-342-3p and their predicted target gene TIAM1 in extranodal NK/T-cell lymphoma, nasal type | Q36502791 | ||
MicroRNA function in NK-cell biology | Q36751927 | ||
The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Q36920426 | ||
The universal character of the tumor-associated antigen survivin | Q36975578 | ||
Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs | Q37061865 | ||
Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma | Q37329665 | ||
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma | Q37340738 | ||
Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States | Q37350788 | ||
Epstein-Barr virus in lymphoproliferative processes: an update for the diagnostic pathologist. | Q37355565 | ||
STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma | Q37485330 | ||
The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type | Q37504355 | ||
MicroRNA regulation of natural killer cells | Q38085574 | ||
Molecular underpinning of extranodal NK/T-cell lymphoma | Q38114561 | ||
The RUNX family: developmental regulators in cancer | Q38319972 | ||
Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia | Q38351879 | ||
Involvement of MicroRNA in T-Cell Differentiation and Malignancy | Q38388753 | ||
Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis? | Q38576333 | ||
Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma | Q38673895 | ||
EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma | Q38764673 | ||
Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma | Q38917500 | ||
Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype | Q38941606 | ||
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway | Q38996832 | ||
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. | Q39149556 | ||
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity | Q39175582 | ||
The diagnosis and management of NK/T-cell lymphomas. | Q39243241 | ||
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma | Q39329997 | ||
Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses | Q39521104 | ||
MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma | Q39536983 | ||
The role of microRNA-150 as a tumor suppressor in malignant lymphoma | Q39556619 | ||
Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type | Q40101543 | ||
Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis | Q40188809 | ||
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. | Q40336693 | ||
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. | Q40506957 | ||
A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma. | Q40570329 | ||
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. | Q40596015 | ||
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma | Q40717160 | ||
Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan | Q40879894 | ||
CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type | Q41085075 | ||
AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination | Q41140861 | ||
Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine | Q41541557 | ||
Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study | Q41721837 | ||
HACE1, a potential tumor suppressor gene on 6q21, is not involved in extranodal natural killer/T-cell lymphoma pathophysiology. | Q41746564 | ||
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies | Q41826795 | ||
Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. | Q42262315 | ||
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. | Q42810702 | ||
P275 | copyright license | Creative Commons Attribution | Q6905323 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | molecular biology | Q7202 |
genomics | Q222046 | ||
extranodal NK/T-cell lymphoma, nasal type | Q4763254 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | 1931 | |
P577 | publication date | 2018-06-30 | |
P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
P1476 | title | The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation | |
P478 | volume | 19 |
Q64085662 | Molecular pathogenic pathways in extranodal NK/T cell lymphoma |
Q64087879 | Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL) |
Q90134157 | Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma |
Q61814317 | Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders |
Search more.